Long-term safety follow-up of people treated with cilta-cel for multiple myeloma
Follows adults with multiple myeloma previously treated with cilta-cel to study late side effects.
Key facts
- Who runs it
- Janssen Research & Development, LLC
- Where
- Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, and Xi'an, ChinaSee the 11 sitesAlso in 9 other countries, 53 sites
- Registry title
- A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 295 people, planned
- Started
- 9 Mar 2022
- Expected to end
- 30 Jun 2041
- Type of study
- Interventional
- Treatments tested
- Cilta-cel
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who already received at least one dose of cilta-cel in a Company-sponsored clinical study. It follows them over the long term to check for late side effects.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Earlier treatment
- Must have received at least one dose of cilta-cel in a Company-sponsored clinical study.
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
- Participants who have provided informed consent for this study
Where in China
Also in 9 other countries, 53 sites
- Peking University Third HospitalBeijing, ChinaNo longer taking part
- West China Hospital Si Chuan UniversityChengdu, ChinaNo longer taking part
- Fujian Medical University Union HospitalFuzhou, ChinaNo longer taking part
- Sun Yat-sen University Cancer HospitalGuangzhou, ChinaNo longer taking part
- First Hospital, Zhejiang University Medical CollegeHangzhou, ChinaNo longer taking part
- Jiangsu Province HospitalNanjing, ChinaNo longer taking part
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical SchoolNanjing, ChinaNo longer taking part
- Ruijin Hospital Shanghai Jiao Tong UniversityShanghai, ChinaNo longer taking part
- Shanghai Changzheng HospitalShanghai, ChinaNo longer taking part
- Shanghai Fourth People's HospitalShanghai, ChinaNo longer taking part
- The Second Affiliated Hospital of Xi'an Jiaotong UniversityXi'an, ChinaNo longer taking part
About the trial
What the trial wants to find out
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
The group in the trial
- Cilta-celTreatment being tested
Participants who had previously received treatment with cilta-cel in a Company-sponsored clinical study (example, NCT04923893, NCT03758417, NCT04181827, NCT05347485, NCT04133636, and NCT03548207) in the global development program will be enrolled into this study once the individual's participation in the particular interventional study has ended or a study has been terminated. Participants will not receive any treatment in this study and will be followed-up at least once per year on delayed adverse events for up to 15 years after receiving the last dose of cilta-cel.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Plain-language title
- Long-term safety follow-up of people treated with cilta-cel for multiple myelomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 11 November 2026.
- Record updated
- 3 November 2026